CTOs on the Move

Family Care Center

www.fcsprings.com

 
Family Care Center provides counseling, medication management, and TMS. We specialize in mental health care for the entire family. Call today to learn more.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.fcsprings.com
  • 1330, Quail Lake Loop
    Colorado Springs, CO USA 80906
  • Phone: 719.540.2146

Executives

Name Title Contact Details

Similar Companies

Micron Technologies

Micron Technologies is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Curie Therapeutics

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie`s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie`s mission is to revolutionize the use of radiomedicines in cancer.

Clyde Chemists

Clyde Chemists is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LGM Pharma

LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities and expert regulatory support.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trilliumâ„¢ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.